We demonstrate that the cardiomyocyte‐specific USP20‐STAT3‐CARM1 axis plays a protective role in cardiac hypertrophy, suggesting that targeting USP20 with cardiac‐specific gene therapy could be a promising strategy for treating cardiac hypertrophy. The gene discussed is STAT3; the disease is cardiac hypertrophy.